Refractory primary intestinal lymphangiectasia effectively managed with subcutaneous octreotide

Area of Science:

• Gastroenterology
• Pediatric Gastroenterology
• Vascular Medicine

Background:

• Primary intestinal lymphangiectasia (IL) is a rare congenital disorder characterized by dilation of intestinal lymphatic vessels.
• Patients often present with protein-losing enteropathy, malabsorption, and abdominal symptoms.
• Diagnosis typically involves imaging and biopsy, but management can be challenging.

Observation:

• A young male patient with a history of lymphoedema and chronic gastrointestinal issues since childhood was diagnosed with primary IL.
• Conventional dietary management with medium-chain triglyceride (MCT) diet proved ineffective.
• Subcutaneous octreotide administration led to significant clinical improvement.

Findings:

• Octreotide therapy demonstrated efficacy in ameliorating the pathological manifestations of primary IL.
• Treatment resulted in improved clinical well-being and favorable serological markers.
• Octreotide provided symptomatic relief and improved disease markers but did not represent a curative treatment.

Implications:

• This case highlights octreotide as a viable therapeutic option for refractory primary intestinal lymphangiectasia.
• Further research is warranted to explore long-term efficacy and optimal dosing of octreotide in primary IL.
• The findings suggest a potential role for octreotide in managing similar lymphatic disorders.